Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

NCT04042753 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Pituitary
Pituitary Tumor
Pituitary Carcinoma
Pituitary Cancer

Interventions

DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: Nivolumab

Sponsor

Memorial Sloan Kettering Cancer Center